Literature DB >> 7986014

Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides.

D J Medina1, C H Tsai, G D Hsiung, Y C Cheng.   

Abstract

The toxic effects of various concentrations of 2',3'-dideoxycytidine (ddC), 2',3'-dideoxy-2',3'-didehydrothymidine (D4T), and 2',3'-dideoxyinosine (ddI) on CEM cells after 4 days of culture were assessed by measuring cell viability, mitochondrial DNA (mtDNA) content, and mitochondrial morphology. Cell viability and mtDNA content in drug-treated cultures were significantly reduced in a concentration-dependent fashion in comparison with cell viability and mtDNA content in untreated cultures. Cells in the treated cultures also showed significant changes in their mitochondrial morphologies which included distortion and reduction of the cristae and numerous vesicles. Unique features of the morphological changes were associated with each drug. The decrease in cell viability and mtDNA content and the increase in mitochondrial ultrastructural changes were directly related to the concentrations of the drugs used. The potencies of these compounds in reducing cell viability, mtDNA content, and normal mitochondria were in the order ddC > D4T > ddI. Comparison of the three assays used demonstrated that mtDNA content is a significantly more sensitive measure of drug toxicity than cell viability and mitochondrial morphology for the three compounds studied.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986014      PMCID: PMC284643          DOI: 10.1128/AAC.38.8.1824

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Subcellular redistribution of lysosomal enzymes during caerulein-induced pancreatitis.

Authors:  A Saluja; S Hashimoto; M Saluja; R E Powers; J Meldolesi; M L Steer
Journal:  Am J Physiol       Date:  1987-10

2.  Peripheral neuropathy in mitochondrial disease.

Authors:  G Pezeshkpour; C Krarup; F Buchthal; S DiMauro; N Bresolin; J McBurney
Journal:  J Neurol Sci       Date:  1987-02       Impact factor: 3.181

3.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial.

Authors:  M J Browne; K H Mayer; S B Chafee; M N Dudley; M R Posner; S M Steinberg; K K Graham; S M Geletko; S H Zinner; S L Denman
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

5.  Alteration of membrane fusion as a cause of acute pancreatitis in the rat.

Authors:  G Adler; G Rohr; H F Kern
Journal:  Dig Dis Sci       Date:  1982-11       Impact factor: 3.199

6.  Effects of ethionine on digestive enzyme synthesis and discharge by mouse pancreas.

Authors:  L Gilliland; M L Steer
Journal:  Am J Physiol       Date:  1980-11

7.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Respiratory enzymes and mitochondrial morphology of HeLa and L cells treated with chloramphenicol and ethidium bromide.

Authors:  M E King; G C Godman; D W King
Journal:  J Cell Biol       Date:  1972-04       Impact factor: 10.539

View more
  27 in total

1.  In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

Authors:  Z Gu; B Allard; J M de Muys; J Lippens; R F Rando; N Nguyen-Ba; C Ren; P McKenna; D L Taylor; R C Bethell
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.

Authors:  Elijah Paintsil; Ginger E Dutschman; Rong Hu; Susan P Grill; Wing Lam; Masanori Baba; Hiromichi Tanaka; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

3.  Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

Authors:  S Palmer; J Harmenberg; S Cox
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV.

Authors:  Robert O Koch; Ivo W Graziadei; Robert Zangerle; Nikolaus Romani; Hans Maier; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2003-02-28       Impact factor: 1.704

Review 5.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

6.  Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.

Authors:  Takao Nitanda; Xin Wang; Hiroki Kumamoto; Kazuhiro Haraguchi; Hiromichi Tanaka; Yung-Chi Cheng; Masanori Baba
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 7.  A transient kinetic approach to investigate nucleoside inhibitors of mitochondrial DNA polymerase gamma.

Authors:  Karen S Anderson
Journal:  Methods       Date:  2010-05-31       Impact factor: 3.608

8.  Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity.

Authors:  Ginger E Dutschman; Susan P Grill; Elizabeth A Gullen; Kazuhiro Haraguchi; Shingo Takeda; Hiromichi Tanaka; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 9.  Adverse effects of antiretroviral therapy for HIV infection.

Authors:  Valentina Montessori; Natasha Press; Marianne Harris; Linda Akagi; Julio S G Montaner
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

10.  Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.

Authors:  Guangwei Yang; Elijah Paintsil; Ginger E Dutschman; Susan P Grill; Chuan-Jen Wang; Jimin Wang; Hiromichi Tanaka; Takayuki Hamasaki; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.